Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006780 | 0.86 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14010205 | 0.80 | ADORA2A (0.43) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL27699336 | 0.77 | ADORA2A (0.50) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL5008834 | 0.77 | ADORA2A (0.46) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL24837545 | 0.76 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15759356 | 0.76 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL731182 | 0.76 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL12149498 | 0.76 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL3292590 | 0.76 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL13005683 | 0.76 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280842-A1 | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection | MERCK & CO., INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280842-A1 | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection | NSUN2, DUT, EFTUD2 | ADORA2A 444/4885ADA 438/4885ADORA3 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.